Trial Site News
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
  • Register
  • Log In
  • News
  • Video
  • Podcast
  • More
Trial Site News
  • News For You
  • Op-Eds
  • Video
  • Podcasts
  • Investor Watch
  • Write for us
  • News for You
  • Op-Eds
  • Video
  • Podcasts
  • Covid-19
  • Investor Watch

Topic: Site Challenges

BioHaven’s Troriluzole Fails Co-Primary Endpoints in Phase 2 Trial for Mild-to-Moderate Alzheimer’s Disease

BioHaven Pharmaceuticals announced the outcome from a focused analysis of the topline co-primary and key secondary data from its Phase […]

BioHaven’s Troriluzole Fails Co-Primary Endpoints in Phase 2 Trial for Mild-to-Moderate Alzheimer's Disease
1 month ago
Share

Fake Investigator Going to Prison for 28 Years: Two Washington State Trial Site Operations Duped Sponsors & CRO

Just over a year ago, TrialSite introduced the exploits of the fake principal investigator named Sani Anwar, owner of Zain […]

Fake Investigator Going to Prison for 28 Years: Two Washington State Trial Site Operations Duped Sponsors & CRO
5 months ago
Share

Nation’s Largest Chain of Hospitals Under Fire by Nurses Union

A large health care workers union has recently made very serious allegations against a major U.S. health care company.  Specifically, […]

Nation’s Largest Chain of Hospitals Under Fire by Nurses Union
6 months ago
Share

Levo Therapeutics Announces Mixed Results from Phase 3 CARE-PWS Study of LV-101 (Intranasal Carbetocin) for the Treatment of Prader-Willi Syndrome

Levo Therapeutics announced top-line results from the Phase 3 CARE-PWS clinical study evaluating LV-101 (intranasal carbetocin) for the treatment of Prader-Willi Syndrome (PWS). […]

Levo Therapeutics Announces Mixed Results from Phase 3 CARE-PWS Study of LV-101 (Intranasal Carbetocin) for the Treatment of Prader-Willi Syndrome
7 months ago
Share

Lundbeck Discontinues Phase 2 Study of Lu AF11167 in Patients with Schizophrenia

Lundbeck announced a decision to discontinue a phase II proof of concept clinical study of Lu AF11167 in patients with schizophrenia who are […]

Lundbeck Discontinues Phase 2 Study of Lu AF11167 in Patients with Schizophrenia
7 months ago
Share

Genentech Reports Mixed Results from Phase 3 Program of Etrolizumab for Moderate to Severe Active Ulcerative Colitis

Genentech announced topline results from its Phase III study program evaluating the etrolizumab in patients with moderate to severely active ulcerative […]

Genentech Reports Mixed Results from Phase 3 Program of Etrolizumab for Moderate to Severe Active Ulcerative Colitis
7 months ago
Share

India’s Authorities Approve Start of WHO Solidarity Trial in Gujarat India & Challenges at GMERs

The World Health Organization’s Solidarity Trial covering COVID-19 launches in Gujarat India at sites including SVP College in Ahmedabad, GMERs, […]

India’s Authorities Approve Start of WHO Solidarity Trial in Gujarat India & Challenges at GMERs
10 months ago
Share

Lawsuit Claim: Iowa State-Owned I/DD Provider Transformed by Rogue ‘Investigators’ into Research ‘Den of Iniquity’

A federal civil lawsuit has been filed against a state agency and several officials alleging a conspiracy to silence complaints about […]

Lawsuit Claim Iowa State-Owned IDD Provider Transformed by Rogue ‘Investigators’ into Research ‘Den of Iniquity’
1 year ago
Share

University of Iowa Audit Reveals Shortcomings in its Human Subjects Research Program

The University of Iowa (UI) generates $467 million in external research funding for research—reaching an all-time high for the academic […]

University of Iowa Audit Reveals Shortcomings in its Human Subjects Research Program
1 year ago
Share

China’s ‘Thousand Talents Program’ Pierces Moffitt Cancer Center & Director Must Pay with Job

Moffit Cancer Center CEO Dr. Alan List is purportedly leaving the institution due a violation of the cancer center’s rules […]

China’s ‘Thousand Talents Program’ Pierces Moffitt Cancer Center & Director Must Pay with Job
1 year ago
Share

Posts navigation

Older posts

Latest Podcasts

Alan Cannell talks COVID-19: Nobody Likes Cheap Solutions | Podcast S2 E41

Dr. Pierre Kory Talks Covid-19, Ivermectin and the FLCCC | Podcast E43

An Interview With Patricia Carter: Patient Engagement and Retention in Clinical Trials

Dr. Negin Hajizadeh: Researchers Finding A Very Effective Treatment For Covid-19 In New Study

Dr. Jean-Jacques Rajter and Dr. Juliana Cepelowicz Rajter Discuss Ivermectin In Broward County | Podcast S2 E 27

159 W Broadway, Suite 200
Salt Lake City, UT 84101

[email protected]

Connect With Us

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

© 2021 TRIALSITE NEWS. ALL RIGHTS RESERVED.